Pfizer Inc. reports beneficial ownership of 3,442,940 shares of ORIC Pharmaceuticals common stock, representing 3.3% of the outstanding class. The percent is calculated on 103,517,562 shares outstanding as of April 27, 2026, as reported on the cover of ORIC's Form 10‑Q for the quarter ended March 31, 2026.
The filing is a Schedule 13G/A amendment signed by Madelyn D. Purcell on behalf of Pfizer, listing Pfizer's sole voting and dispositive power over the reported shares and providing Pfizer's Delaware status and business address.
Positive
None.
Negative
None.
Insights
Pfizer discloses a passive stake of 3.3% in ORIC Pharmaceuticals.
Pfizer's Schedule 13G/A shows 3,442,940 shares with sole voting and dispositive power. The filing cites ORIC's reported 103,517,562 shares outstanding as of April 27, 2026, which is the basis for the 3.3% figure.
Ownership is reported as passive under Schedule 13G/A conventions; cash‑flow treatment and any plans for trading are not stated in the excerpt. Subsequent filings would disclose changes in position.
Key Figures
Reported shares beneficially owned:3,442,940 sharesPercent of class:3.3%Shares outstanding used:103,517,562 shares+1 more
4 metrics
Reported shares beneficially owned3,442,940 sharesPfizer sole voting/dispositive power (Schedule 13G/A)
Percent of class3.3%Calculated using 103,517,562 shares outstanding as of April 27, 2026
Shares outstanding used103,517,562 sharesAs of April 27, 2026 per ORIC's Form 10‑Q cover page
CUSIP68622P109ORIC Pharmaceuticals common stock
Key Terms
Schedule 13G/A, beneficially owned, sole dispositive power
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially ownedfinancial
"Amount beneficially owned: See the respective responses of the Reporting Persons"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive powerregulatory
"Sole Dispositive Power 3,442,940.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
ORIC Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock par value $0.0001 per share
(Title of Class of Securities)
68622P109
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
68622P109
1
Names of Reporting Persons
Pfizer Inc. (IRS Identification No.: 13-5315170)
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
3,442,940.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
3,442,940.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,442,940.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.3 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Percent of class outstanding represented by the amount in row (11) is based on a total of 103,517,562 shares of common stock outstanding as of April 27, 2026, as reported on the cover of the Issuer's quarterly report on Form 10-Q for the quarterly period ended March 31, 2026 filed by the Issuer with the U.S. Securities and Exchange Commission on May 4, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ORIC Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
240 E. Grand Ave., 2nd Floor, South San Francisco, California, 94080
Item 2.
(a)
Name of person filing:
Pfizer Inc.
(b)
Address or principal business office or, if none, residence:
66 Hudson Boulevard East, New York, NY10001-2192
(c)
Citizenship:
Delaware
(d)
Title of class of securities:
Common Stock par value $0.0001 per share
(e)
CUSIP No.:
68622P109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See the respective responses of the Reporting Persons to Item 9 on the attached cover pages.
(b)
Percent of class:
See the respective responses of the Reporting Persons to Item 11 on the attached cover pages.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See the respective responses of the Reporting Persons to Item 5 on the attached cover pages.
(ii) Shared power to vote or to direct the vote:
See the respective responses of the Reporting Persons to Item 6 on the attached cover pages.
(iii) Sole power to dispose or to direct the disposition of:
See the respective responses of the Reporting Persons to Item 7 on the attached cover pages.
(iv) Shared power to dispose or to direct the disposition of:
See the respective responses of the Reporting Persons to Item 8 on the attached cover pages.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Not applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Not applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
Not applicable
Item 9.
Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
Not applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Pfizer reports owning 3,442,940 shares, equal to 3.3% of ORIC common stock. The percentage uses 103,517,562 shares outstanding as of April 27, 2026 from ORIC's Form 10‑Q cover page.
Does Pfizer have voting control over the reported ORIC shares?
Yes. Pfizer reports sole voting power and sole dispositive power over the 3,442,940 shares. The Schedule 13G/A shows zero shared voting or dispositive power for these shares.
What document and date support the outstanding share count used?
The filing cites ORIC's quarterly report on Form 10‑Q for the quarter ended March 31, 2026 filed May 4, 2026. It states 103,517,562 shares outstanding as of April 27, 2026 as the basis for the percentage.
Is this Schedule 13G/A an amendment and who signed it?
Yes. The document is labeled Amendment No. 1 to a Schedule 13G and is signed by Madelyn D. Purcell, Assistant Secretary on behalf of Pfizer on 05/12/2026.
Does the filing state whether Pfizer plans to buy or sell additional ORIC shares?
The Schedule 13G/A lists Pfizer's current ownership and powers; it does not state any intent to buy or sell additional shares. No trading plans or cash‑flow treatment are disclosed in the provided excerpt.
